Posts by: Joana Carvalho

Joana Carvalho

Joana holds a BSc in Biology, a MSc in Evolutionary and Developmental Biology and a PhD in Biomedical Sciences from Universidade de Lisboa, Portugal. Her work has been focused on the impact of non-canonical Wnt signaling in the collective behavior of endothelial cells — cells that made up the lining of blood vessels — found in the umbilical cord of newborns.

September 14, 2020September 14, 2020

Post-surgery Opdivo Shows Benefits for Esophageal, GEJ Cancer Patients in Ongoing Trial

News

Opdivo (nivolumab) significantly prolongs the time patients with resected esophageal or gastroesophageal junction (GEJ) cancer live without signs of disease after receiving chemoradiation therapy followed by cancer removal surgery, interim ... Read more

September 9, 2020September 9, 2020

Strong Response for Tessa’s CD30 CAR-T Cell Therapy in Hodgkin’s Lymphoma Trial

News

Tessa Therapeutics’ investigational CD30 CAR-T cell therapy is safe and leads to a high rate of strong and sustained responses in people with relapsed or treatment-resistant Hodgkin’s lymphoma, according to ... Read more

August 17, 2020September 23, 2020

Health Canada Approves Opdivo-Yervoy-Chemo Combo for Advanced NSCLC

News

Note: This story was updated Sept. 23, 2020, to note that the triple combination reduced the risk of death by 34%, not 37%. Health Canada has approved a combination therapy ... Read more

August 12, 2020August 12, 2020

Opdivo-Yervoy Combo Prolongs Survival of Patients With Inoperable Mesothelioma, Phase 3 Trial Shows

News

A dual immunotherapy regimen of Opdivo (nivolumab) and Yervoy (ipilimumab) can prolong the survival of patients with untreated, inoperable malignant pleural mesothelioma (MPM), according to data from a Phase 3 clinical ... Read more

August 7, 2020August 7, 2020

FDA Clears FT819 CAR T-cell Therapy for Clinical Testing in Lymphoma, Leukemia

News

Fate Therapeutics will soon initiate a Phase 1 trial investigating its CAR T-cell therapy, FT819, across several B-cell cancers, including chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), and non-Hodgkin’s ... Read more

July 31, 2020July 31, 2020

Yale Researcher Wins NIH Merit Award, Supporting Immunotherapy Work

News

The National Institutes of Health (NIH) has given an R37 Merit Award to support the work of Kurt Schalper, MD, PhD, in the field of immunotherapy for the next seven ... Read more

July 27, 2020July 27, 2020

Phase 3 Trial Launched to Test Cabometyx-Tecentriq in Advanced Kidney Cancer

News

Exelixis has launched a Phase 3 trial that will investigate the safety and efficacy of a combination therapy of Cabometyx (cabozantinib) and Tecentriq (atezolizumab) in people with advanced renal cell carcinoma (RCC) ... Read more

July 22, 2020July 22, 2020

EMA to Review Liso-cel as CAR T-cell Therapy for Advanced Lymphomas

News

The European Medicines Agency (EMA) has agreed to review a request to approve the investigational CAR T-cell therapy, lisocabtagene maraleucel (liso-cel), for people with pretreated lymphomas. The marketing authorization application, submitted ... Read more

July 17, 2020July 17, 2020

FDA Grants Priority Review to Keytruda for Relapsed or Refractory Classical Hodgkin’s Lymphoma

News

The U.S. Food and Drug Administration (FDA) has accepted and given priority review to Merck‘s application requesting the approval of Keytruda (pembrolizumab) as a second-line treatment for adults with relapsed or ... Read more

July 2, 2020July 2, 2020

FDA Approves Bavencio Maintenance Therapy for Advanced Bladder Cancer

News

The U.S. Food and Drug Administration (FDA) has approved Bavencio (avelumab) as a first-line maintenance therapy for people with advanced urothelial carcinoma — a type of bladder cancer — whose disease ... Read more